Pre-made Cixutumumab benchmark antibody ( Whole mAb, anti-IGF1R therapeutic antibody, Anti-IGFR/CD221/IGFIR/JTK13 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-108

Pre-Made Cixutumumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cixutumumab (IMC-A12) is a human monoclonal antibody for the treatment of solid tumors.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-108-1mg 1mg 3090 Inquiry Inquiry

Size： 1mg | 10mg | 100mg

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Cixutumumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody
INN Name Cixutumumab
TargetIGF1R
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2008
Year Recommended2009
CompaniesEli Lilly;ImClone Systems;M. D. Anderson Cancer Center;National Cancer Institute (USA)
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBreast cancer;Colorectal cancer;Head and neck cancer;Liver cancer;Neuroendocrine tumours;Non-small cell lung cancer;Oesophageal cancer;Pancreatic cancer;Prostate cancer;Rhabdomyosarcoma;Sarcoma;Soft tissue sarcoma;Solid tumours;Thymoma
Development TechDyax Human Phage Display